Page 25 - Read Online

Bhasin et al. J Transl Genet Genom 2024;8:55-76 https://dx.doi.org/10.20517/jtgg.2023.46 Page 73

targeting EpCAM and the T cell coreceptor CD3. Cancer Chemother Pharmacol 2015;75:1065-73. DOI
65. Kebenko M, Goebeler ME, Wolf M, et al. A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3
T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors. Oncoimmunology 2018;7:e1450710. DOI
PubMed PMC
66. Zorko NA, Ryan CJ. Novel immune engagers and cellular therapies for metastatic castration-resistant prostate cancer: do we take a
BiTe or ride BiKEs, TriKEs, and CARs? Prostate Cancer Prostatic Dis 2021;24:986-96. DOI PubMed PMC
67. Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and
malignant human tissues. Clin Cancer Res 1997;3:81-5. PubMed
68. Davis MI, Bennett MJ, Thomas LM, Bjorkman PJ. Crystal structure of prostate-specific membrane antigen, a tumor marker and
peptidase. Proc Natl Acad Sci USA 2005;102:5981-6. DOI PubMed PMC
69. Mhawech-Fauceglia P, Zhang S, Terracciano L, et al. Prostate-specific membrane antigen (PSMA) protein expression in normal and
neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour
tissue microarray technique. Histopathology 2007;50:472-83. DOI
70. Kinoshita Y, Kuratsukuri K, Landas S, et al. Expression of prostate-specific membrane antigen in normal and malignant human
tissues. World J Surg 2006;30:628-36. DOI
71. Kaittanis C, Andreou C, Hieronymus H, et al. Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic
signaling through metabotropic glutamate receptors. J Exp Med 2018;215:159-75. DOI PubMed PMC
72. Heston WD. Characterization and glutamyl preferring carboxypeptidase function of prostate specific membrane antigen: a novel
folate hydrolase. Urology 1997;49:104-12. DOI PubMed
73. Rahn KA, Slusher BS, Kaplin AI. Glutamate in CNS neurodegeneration and cognition and its regulation by GCPII inhibition. Curr
Med Chem 2012;19:1335-45. DOI PubMed
74. Dorff TB, Narayan V, Forman SJ, et al. Novel redirected T-cell immunotherapies for advanced prostate cancer. Clin Cancer Res
2022;28:576-84. DOI PubMed PMC
75. O'Keefe DS, Bacich DJ, Huang SS, Heston WDW. A perspective on the evolving story of PSMA biology, PSMA-based imaging, and
endoradiotherapeutic strategies. J Nucl Med 2018;59:1007-13. DOI PubMed PMC
18
76. Rowe SP, Campbell SP, Mana-Ay M, et al. Prospective evaluation of PSMA-targeted F-DCFPyL PET/CT in men with biochemical
failure after radical prostatectomy for prostate cancer. J Nucl Med 2020;61:58-61. DOI PubMed PMC
77. Hofman MS, Emmett L, Sandhu S, et al; TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate
Cancer Trials Group. [ 177 Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer
(TheraP): a randomised, open-label, phase 2 trial. Lancet 2021;397:797-804. DOI
78. Hofman MS, Violet J, Hicks RJ, et al. [ 177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant
prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol 2018;19:825-33. DOI
79. Sartor O, de Bono J, Chi KN, et al; VISION Investigators. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate
cancer. N Engl J Med 2021;385:1091-103. DOI
80. Ma Q, Gomes EM, Lo AS, Junghans RP. Advanced generation anti-prostate specific membrane antigen designer T cells for prostate
cancer immunotherapy. Prostate 2014;74:286-96. DOI PubMed
81. Boyerinas B, Miller S, Murray R, et al. Abstract 602: a novel TGF-β/IL-12R signal conversion platform that protects CAR T cells
from TGF-β-mediated immune suppression and concurrently amplifies effector function. Cancer Res 2017;77:602. DOI
82. Calcinotto A, Spataro C, Zagato E, et al. IL-23 secreted by myeloid cells drives castration-resistant prostate cancer. Nature
2018;559:363-9. DOI PubMed PMC
83. Wang D, Shao Y, Zhang X, Lu G, Liu B. IL-23 and PSMA-targeted duo-CAR T cells in prostate cancer eradication in a preclinical
model. J Transl Med 2020;18:23. DOI PubMed PMC
+
84. Slovin SF, Wang X, Hullingsand M, et al. Chimeric antigen receptor (CAR ) modified T cells targeting prostate-specific membrane
antigen (PSMA) in patients (pts) with castrate metastatic prostate cancer (CMPC). J Clin Oncol 2013;31:72. DOI
85. Junghans RP, Ma Q, Rathore R, et al. Phase I trial of anti-psma designer CAR-T cells in prostate cancer: possible role for interacting
interleukin 2-T cell pharmacodynamics as a determinant of clinical response. Prostate 2016;76:1257-70. DOI
86. Slovin SF, Dorff TB, Falchookand GS, et al. Phase 1 study of P-PSMA-101 CAR-T cells in patients with metastatic castration-
resistant prostate cancer (mCRPC). J Clin Oncol 2022;40:98. DOI
87. Narayan V, Barber-Rotenberg JS, Jung IY, et al; Prostate Cancer Cellular Therapy Program Investigators. PSMA-targeting TGFβ-
insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat Med 2022;28:724-34. DOI
88. Friedrich M, Raum T, Lutterbuese R, et al. Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a
novel PSMA/CD3-Bispecific BiTE antibody cross-reactive with non-human primate antigens. Mol Cancer Ther 2012;11:2664-73.
DOI
®
89. Hummel HD, Kufer P, Grüllich C, et al. Pasotuxizumab, a BiTE immune therapy for castration-resistant prostate cancer: phase I,
dose-escalation study findings. Immunotherapy 2021;13:125-41. DOI
90. Deegen P, Thomas O, Nolan-Stevaux O, et al. The PSMA-targeting half-life extended BiTE therapy AMG 160 has potent antitumor
activity in preclinical models of metastatic castration-resistant prostate cancer. Clin Cancer Res 2021;27:2928-37. DOI PubMed
91. Tran B, Horvath L, Dorff T, et al. 609O results from a phase I study of AMG 160, a half-life extended (HLE), PSMA-targeted,
®
bispecific T-cell engager (BiTE ) immune therapy for metastatic castration-resistant prostate cancer (mCRPC). Ann Oncol